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Abstract
Background
Recent studies suggest that vitamin D deficiency represents an additional cofactor of renal
anemia, with several mechanisms accounting for this relationship. In line with it, the admin-
istration of vitamin D or its analogues has been associated with an improvement of anemia.
There are no data, however, about a direct effect of paricalcitol on hemoglobin (Hb) levels.
Therefore, we conducted a study to determine whether paricalcitol, compared to calcitriol,
improves anemia in patients with chronic kidney disease (CKD).
Methods
In this randomized trial 60 CKD patients stage 3b-5 and anemia (Hb levels: 10-12.5 g/dL)
were assigned (1:1) to receive low doses of calcitriol (Group Calcitriol) or paricalcitol (Group
Paricalcitol) for 6 months. All the patients had normal values of plasma calcium, phosphorus
and PTH, a stable iron balance, and normal values of C-Reactive Protein. The primary end-
point was to evaluate the effects of the two treatments on Hb levels; the modifications in
24hr-proteinuria (UProt) were also evaluated.
Results
A significant Group x Time interaction effect was observed in the longitudinal analysis of Hb
levels (F(1,172)=31.4, p<0.001). Subjects in Paricalcitol experienced a significant monthly
increase of Hb levels equal to +0.16 g/dL [95% C.I. 0.10 to +0.22, p<0.001) while in Group
Calcitriol, Hb decrease throughout the follow-up with an average monthly rate of -0.10 g/dL
(95% C.I.: -0.17 to -0.04, p<0.001). In Group Paricalcitol, UProt was significantly reduced
after 6 months [0.35 (0.1-1.2) vs 0.59 (0.2-1.6), p<0.01], whereas no significant difference
emerged in Group Calcitriol. Plasma levels of calcium, phosphate, PTH and of inflammation
markers remained in the normal range in both groups throughout the study.
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Conclusions
Short-term exposure to paricalcitol results in an independent increase in Hb levels, which
occurred with no modification of iron balance, inflammatory markers, and PTH plasma con-
centrations, and was associated with a decrease in UProt.
Trial Registration
ClinicalTrials.gov NCT01768351
Introduction
Recent literature strongly emphasizes the pleiotropic effects of vitamin D independent of calci-
um and phosphate homeostasis [1], which include reduced atherogenesis, lower renin-
angiotensin-system activity, reduced proteinuria, decreased inflammation, and improved endo-
thelial function [2–4]. Nevertheless, vitamin D deficiency or insufficiency is prevalent all over
the world in each population segment and is considered a real pandemic disease [5].
Vitamin D also affects the haemopoietic system; its receptors (VDRs), in fact, are present in
bone marrow, including stromal and accessory cells [6] and vitamin D deficiency represents an
additional cofactor of anemia, beyond erythropoietin (EPO) and iron deficiency or inflamma-
tion [7, 8]; significant relationships, moreover, exist between plasma levels of 25-hydroxyvitamin
D and hemoglobin (Hb) concentrations in health [9] and disease [8, 10].
Several mechanisms may account for this association: “in vitro” studies on red cells precur-
sors of bone marrow demonstrate that calcitriol directly increases EPO-receptor expression
and synergistically stimulates cell proliferation along with EPO [11, 12]. In addition, vitamin D
shows anti-inflammatory properties that improve responsiveness to EPO through the reduced
production of hepcidin and pro-inflammatory cytokines [7, 13], whose concentrations increase
during vitamin D deficiency in bone marrow and impair erythropoiesis [14]; VDRs activation,
conversely, up-regulates the lymphocytic release of anti-inflammatory interleukin-10 (IL-10)
which exerts proliferative effects on erythroid progenitors [12, 15].
Finally, in patients with chronic kidney disease (CKD) the positive effects of vitamin D on
erythropoiesis could also be related to its suppressive effects on PTH, which directly inhibits
erythroid progenitors, EPO synthesis, and red blood cells survival [16]. Recent reports, howev-
er, suggest that EPO resistance to high PTH levels is probably related to vitamin D deficiency,
whose levels were not assessed in previous studies [12].
In line with these observations, the administration of vitamin D and of its analogues has
been associated with an improvement of anemia and/or a reduction in EPO requirements.
Alfacalcidol [17], cholecalciferol, and ergocalciferol showed a positive impact on anemia in he-
modialysis (HD) patients [18], while calcitriol improved hemoglobin Hb levels and reduced
the need for EPO in CKD patients on conservative management and on dialysis [12, 19]; final-
ly, a recent study evaluating 1-year treatment with paricalcitol in 12 HD patients previously
treated with calcitriol, showed an amelioration of erythropoiesis during paricalcitol treatment
[20]. It is noteworthy that most of the studies evaluating the association of vitamin D deficiency
with renal anemia emphasize the role of inflammation and of PTH as the main mediators of
these changes [14].
To date, no randomized clinical trial (RCT) has evaluated the effects of oral paricalcitol
compared to calcitriol on Hb levels, as main outcome measure in CKD patients. Therefore, we
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conducted a pilot RCT to determine whether the use of paricalcitol improves anemia in CKD
patients. To ascertain a direct and independent effect of paricalcitol on erythroid cells, the
study was carried out in patients with normal levels of PTH and devoid of overt clinical inflam-
mation, two confounding factors in pathogenesis of renal-anemia.
Patients and Methods
The protocol for this trial (as approved by our local ethic committee) and supporting CON-
SORT checklist are available as supporting information; see S1 CONSORT Checklist and S1
Protocol.
Patients
This prospective study was conducted in the CKD Clinic of the University Federico II of Na-
ples, Italy, where 185 consecutive patients (stage 3b-5) were screened from October 2010 to Oc-
tober 2012.
Inclusion criteria for the study were: age>18 years, estimated GFR (eGFR, MDRD equa-
tion) 45 ml/min/1,73 m2, Hb levels between 10 and 12.5 g/dL, normal transferrin saturation
(TSAT, 20–40%), plasma ferritin levels100 ng/mL, normal mean corpuscular volume (MCV,
85–95 fL), parathormone (PTH) serum levels between 20 and 300 pg/mL, according to the sug-
gested values for kidney disease stage, and calcium and phosphate plasma levels within their
normal values (i.e.<10.5 mg/dl, and<4.5 mg/dl, respectively), controlled by a low protein diet
(0.7–0.9 g/kg b.w./day), calcium supplements and phosphate binders.
Exclusion criteria were: presence of inflammatory, infectious disease or surgical interven-
tions in the last 3 months, high-sensitivity C-reactive protein (CRP) levels>3 mg/dl (normal
values: 0–5 mg/ml), hematological disorders or bleeding in the last 6 months, malignancies,
treatment with immunosuppressive drugs, poorly controlled hypertension (>170/100 mmHg),
presence of clinical/ECG signs of cardiovascular disease in the last 3 months.
Withdrawal from the study was considered in case of malnutrition (loss of body weight>5%
in 1 month or BMI< 20 kg/m2 with serum albumin levels<3.2 g/dl), need to start dialysis
(eGFR6 ml/min, K+>6.0 mEq/L, intractable hypertension) or Hb values falling below 10 g/dl.
Pharmacological and non-pharmacological therapies were prescribed to each patient to achieve
the therapeutic targets in keeping with K/DOQI CKD guidelines for stages 3b-5. Patients previ-
ously treated with vitamin D or its analogues discontinued such therapy at least 1 month before
starting the study. Informed written consent was obtained from each patient. The trial was ap-
proved in September 2010 by our local Medic Ethics Committee (Ethic Commettee “Carlo Ro-
mano” of Federico II University of Naples) and was in adherence with the Declaration of
Helsinki. It was registered in ClinicalTrials.gov with Identifier: NCT01768351. The authors con-
firm that all ongoing and related trials for this drug/intervention are registered.
Study design and procedures
This was a prospective RCT in which the randomization list was generated by a computer and
kept concealed in numbered, sealed envelopes opened in sequence by administrative staff per-
sonnel. According to our criteria, 60 patients were enrolled in the study and were randomly as-
signed (1:1) to receive treatment with fixed low doses of calcitriol (Group Calcitriol) or
paricalcitol (Group Paricalcitol), irrespective of baseline PTH levels (Fig. 1). The treatment
phase lasted 6 months and subjects were dosed in a 4:1 ratio of paricalcitol (1 mcg/day) to calci-
triol (0.5 mcg/every other day), based on previous clinical studies that compared the two vita-
min D compounds.
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All the patients were examined at baseline (T0) and after two (T2), four (T4) and six months
(T6) of treatment, in which body weight and sitting blood pressure (BP, average of 3 measure-
ments in 15 min) were evaluated and blood was withdrawn to determine the main laboratory
data. Urinary protein excretion was also evaluated in 24-hour samples (UProt). At T0 and T6,
plasma levels of vitamin B12 and folate were also measured in all the patients.
Standard laboratory procedures were used for blood and urinary measurements.
All the patients were maintained at the same dietary regimen and the same pharmacological
therapies throughout the study, including phosphate binders, angiotensin converting enzyme
inhibitors (ACE-I), angiotensin receptor blockers (ARBs), and erythropoiesis-stimulating
agents (ESA); if Hb values resulted>13 g/dl, however, ESA dosage was reduced by 25%; simi-
larly, oral iron therapy was introduced (oral sulfate iron, 105 mg/day) if TSAT fell below 15%.
No further calcium supplement was administered to any patient during the follow-up.
Fig 1. Flow chart of patient selection.
doi:10.1371/journal.pone.0118174.g001
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End-points
The primary endpoint of the study was to evaluate the effects of low doses of two different
treatments, namely calcitriol and paricalcitol, on Hb plasma levels during a follow-up period of
6 months in CKD patients with stable levels of calcium, phosphorus and PTH. As secondary
end point, the modifications in UProt with both drugs were also evaluated.
Statistical analysis
Data with normal distribution were summarized as means ± standard deviation and those with
non-normal distribution as medians and inter-quartile range. Between groups comparisons of
independent variables were performed by Student’s t-test and Mann–Whitney U-test for nor-
mally and not-normally distributed variables, respectively. Within patients comparisons were
performed by paired t-Test or Wilcoxon Rank Test, as appropriate. Differences of categorical
variables between two groups were investigated by the χ2 test. A p value<0.05 was considered
statistically significant.
The independent relationship between the treatments (paricalcitol versus calcitriol) and he-
moglobin data over time (i.e. hemoglobin values at T2, T4 and T6, dependent variable) was in-
vestigated by a multiple linear mixed model (LMM) with group, time and group x time
interaction as main predictors and by adjusting for hemoglobin value at baseline and other po-
tential confounders (i.e. the variables resulting different between the two Groups at baseline
with P<0.10 at comparative analysis). Both time (expressed in months from baseline) and sub-
ject were considered as random effect and an unstructured variance-covariance structure was
applied to account for within-patient dependence of hemoglobin values over time. In multiple
LMM analysis data were expressed as regression coefficient, 95% confidence interval and P
value. Data were analyzed using the Statistical Package for Social Sciences (SPSS) for Windows,
version 20.0 software (SPSS Inc., IL, USA).
Results
Baseline data (Tables, 1,2)
At baseline, the two groups were comparable for age, body weight, eGFR, and use of ESA, phos-
phate binders, calcium, iron supplements and vitamin D analogs. Significant differences, con-
versely, were detected in number of females, greater in Paricalcitol Group, in number of
diabetic patients and in use of ACE-I, both higher in Calcitriol Group. The use of antihyperten-
sive therapies was similar between the groups (data not shown).
Patients showed an excellent metabolic control, and no difference was detected between the
two groups in any laboratory data, including Vitamin B12 and folate concentrations, all in the
normal range.
Follow-up data (Table 3)
None of the 60 participating patients dropped out of the study throughout the follow-
up period.
Low doses of Paricalcitol and Calcitriol did not alter the PTH-calcium-phosphate axis. In
fact, no change was observed in any of these parameters throughout the study, despite a slight
decrease of PTH in both Groups (NS), as expected.
Hb plasma concentrations, conversely, showed a divergent pattern (Fig. 2). Patients of
Group Paracalcitol showed a significant rise in Hb levels in T2 compared to baseline (+0.26 g/
dL, 95% C.I. [+0.07 to +0.45], p = 0.008), which progressively increased at T6 (+0.89 g/dL, 95%
C.I. [+0.64 to 1.15], p<0.001). In Group Calcitriol, conversely, a slight decline in Hb
Paricalcitol Effect on CKD Anemia
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concentration was observed throughout the follow-up period leading ad T6 to a significant 5%
relative mean reduction with respect to baseline (-0.61 g/dL 95% C.I. [-0.18 to -0.42],
p<0.001); as a consequence, the differences in Hb levels between Paricalcitol and Calcitriol
group became statistically significant at T2 (+0.57 g/dL, 95% C.I. +0.18 to +0.96], p<0.001)
Table 1. Demographic characteristics, diagnosis of renal disease and drug treatments in the 2 groups under study (n = 30 each).
ALL Paricalcitol Calcitriol
Age (years) 56.8±16.8 59.9±15.1 54.7±18.3
Female gender 20 (33%) 15 (50%) 5 (17%)°
Body weight (kg) 74.4±13.7 73.3±13.6 75.4±13.8
eGFR (ml/min/1.73m2) 26.4±9.9 25.4±9.6 27.4±10.3
CKD stage (3b/4/5/) 19/39/2 9/20/1 10/19/1
GN 15 (25%) 7 (23%) 8 (27%)
DM 12 (20%) 3 (10%) 9 (30%)°
ADPKD 8 (13%) 3 (10%) 5 (17%)
Urologic causes 2 (2%) 2 (7%) 0 (0%)
Other/unknown 23 (30%) 15 (50%) 8 (27%)
ACE-I 32 (53%) 12 (40%) 20 (67%)°
ARB 27 (45%) 16 (53%) 11 (37%)
Calcium suppl. 11 (18%) 6 (20%) 5 (17%)
Phosphate binders 15 (25%) 7 (23%) 8 (27%)
Iron 13 (22%) 7 (23%) 6 (20%)
ESA 8 (13%) 4 (13%) 4 (13%)
Vitamin D analogs 15 (25%) 8 (27%) 7 (23%)
Data are expressed as means ± SD; data in brackets express the % values in that group.
° p<0.05 between groups
Abbreviations: eGFR, estimated glomerular ﬁltration rate; CKD, chronic kidney disease; GN, glomerulonephritis; DM: diabetes mellitus; ADPKD, adult
polycystic kidney disease; ACE-I, inhibitors of angiotensin converting enzyme; ARB, angiotensin receptor blockers; ESA, erythropoiesis stimulating
agents.
Primary kidney disease was classiﬁed according to the European Renal Association codes.
doi:10.1371/journal.pone.0118174.t001
Table 2. Main laboratory data of the patients under study (ALL, N = 60), and in the two groups after randomization (n = 30 in both groups).
ALL Paricalcitol Calcitriol
Hb (g/dL) 11.8±0.7 11.7±0.8 12.0±0.7
Ferritin (ng/mL) 190.5±116.9 175.2±118.2 205.7±116.1
TSAT (%) 28.1±7.4 27.4±7.6 28.8±7.4
Vit. B12 (pg/mL) 514.7±405.4 432.0±174.4 595.4±138.6
Folate (ng/mL) 6.6 (4.7–9.1) 6.8 (4.8–8.8) 6.3 (4.7–9.8)
Calcium (mg/dL) 9.4±0.4 9.4±0.3 9.3±0.4
Phosphate (mg/dL) 3.6±0.7 3.6±0.5 3.6±0.9
PTH (pg/mL) 116.5 (92–149) 116 (44–146) 114 (38–137)
Albumin (g/dL) 4.3±0.3 4.3±0.3 4.3±0.4
hsPCR (mg/L) 1.20 (0.90–1.70) 1.20 (0.80–1.70) 1.30 (0.90–1.85)
UProt (g/24 h) 0.52 (0.18–1.47) 0.59 (0.23–1.56) 0.44 (0.14–1.35)
Data are expressed as means ± standard deviation or as median and interquartile range.
doi:10.1371/journal.pone.0118174.t002
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and increased in T4 (+1.17 g/dL, 95% C.I. [+0.73 to +1.61], p<0.001). In multiple linear mixed
model, after adjusting for Hb levels at baseline and other confounding factors (gender, diabetes,
and use of ACEi) a significant Treatment x Time interaction was observed in the longitudinal
course of Hb levels (F(1,172) = 31.4, p<0.001). In particular the monthly average increase in
Hb levels for Paricalcitol group was +0.16 g/dL [95% C.I. 0.10 to +0.22, p<0.001) while subjects
in Calcitriol group experienced a significant reduction in Hb levels equal to -0.10 g/dL per
month (95% C.I.: -0.17 to -0.04, p<0.001).
These changes occurred with stable ferritin plasma levels and TSAT values in both groups.
Indeed, a decrease in TSAT was observed at T6 vs T0 in Calcitriol Group (28.77% at T0 vs
25.33% at T6; mean difference-3.43%, 95% C.I. [-0.53 to -6.34], p = 0.022), which, however, re-
mained in the normal range in all the patients; accordingly, no further iron supplement was ad-
ministered during the follow-up.
In Paricalcitol Group, 24-hour UProt was significantly reduced after 6 months of treatment
(0.59 [0.23; 1.56] g/24h at T0 vs 0.35 [0.14; 1.16] g/24h at T6, p<0.001), whereas patients
under Calcitriol exhibited numerically higher values of UProt throughout the follow-up period
(+49%, T6 vs T0, NS). These modifications occurred despite concomitant decreases of eGFR in
both Groups (-2.3 ml/min/1.73m2, 95% C.I.: -3.9 to—0.8, p = 0.003 in Group Paricalcitol and
—2.0 ml/min/1.73m2, 95% C.I.: -3.5 to -0.5, p = 0.010 in Group Calcitriol, respectively, vs their
T0); it is noteworthy that the UProt/eGFR ratio tended to decrease in Group Paricalcitol, but
increased to a steady level in Group Calcitriol at T6 when compared to T0 (Fig. 3).
In both Groups hsCRP plasma concentrations did not vary and BP was well controlled dur-
ing the whole study period.
Table 3. Main clinical and laboratory data in the two Groups under study throughout the follow-up period (n = 30 in both groups).
Paracalcitol Calcitriol
T0 T2 T4 T6 T0 T2 T4 T6
Hb 11.7±0.8 11.9±0.9* 12.2±0.9*# 12.6±0.9*# 12.0±0.6 11.8±0.5* 11.6±0.5* 11.4±0.5*
GFR 25.4±9.6 25.5±9.9 23.7±8.4* 23.0±8.4* 27.4±10.3 27.0±11.4 26.7±10.9 25.4±11.8
Ferritin 175.2±68.2 162.9±60.8 152.3±48.5 155.8±53.1 185.8±53.0 193.3±84.9 189.2±79.8 180.4±72.2
TSAT 27.4±7.2 27.1±6.2 27.0±6.4 25.6±5.3 25.8±7.3 28.3±8.2 27.1±5.6 25.3±5.2
Ca 9.4±0.3 9.4±0.4 9.4±0.4 9.5±0.4 9.3±0.4 9.3±0.4 9.4±0.4 9.4±0.3
P 3.6±0.5 3.7±0.5 3.8±0.5* 3.7±0.6 3.7±0.6 3.8±0.7 3.6±0.6 3.8±0.6
PTH 116 (44–146) 110 (40–102) 108 (33–101) 103 (27–98) 114 (38–137) 112 (39–121) 108 (21–118) 104 (34–120)
hsCRP 1.2 (0.8–1.7) 1.2 (0.9–2.0) 1.2 (0.8–1.7) 1.0 (0.8–1.5) 1.3 (0.9–1.9) 1.0 (0.9–2.0) 0.9 (0.8–1.5) 1.0 (0.8–1.9)
UProt 0.59 (0.2–1.6) 0.74 (0.2–1.4) 0.50 (0.1–1.3)# 0.35 (0.1–1.2)*# 0.44 (0.1–1.3) 0.55 (0.1–1.9) 0.66 (0.0–1.8) 0.79 (0.3–1.8)
SBP 130.5±18.1 131.5±18.5 130.8±17.9 129.5±15.4 130.8±14.5 130.3±16.0 133.0±17.5 132.3±18.6
DBP 76.3±8.7 75.3±9.7 76.5±7.2 73.5±8.8 77.0±8.3 75.8±9.6 76.3±11.0 76.7±11.6
Data are expressed as means ± SD or as median and interquartile range.
* = p<0.05, minimum value, vs baseline T0;
# = p<0.05, minimum value, difference between groups (same period).
Abbreviations and measure units: Hb, Hemoglobin (g/dl); GFR, glomerular ﬁltration rate (ml/min); Ferritin (ng/dl); TSAT, transferrin saturation (%); Ca,
calcium plasma levels (mg/dl); P, phosphate plasma levels (mg/dl); PTH, parathormon (ng/ml); hsCRP, high sensitivity C reactive protein (mg/dl); UProt,
24 hours urinary protein excretion (g/day); SBP and DBP, systolic and diastolic blood pressure, respectively (mm Hg).
T0: baseline; T2, T4, and T6: 2, 4, and 6 months of follow-up.
doi:10.1371/journal.pone.0118174.t003
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According to the protocol, patients were maintained at the same pharmacological therapies
throughout the follow-up period. Only one patient of Group Paricalcitol needed to reduce ESA
dosage, and two patients stopped ESA treatment (one in each group).
Discussion
The key finding of this RCT is that short-term treatment with paricalcitol results in an indepen-
dent increase in Hb levels associated with a decreased urinary protein excretion, which occurred
with no modification in iron balance, inflammatory markers, and PTH plasma concentrations.
Despite similar clinical conditions, patients treated with calcitriol showed no benefit in Hb lev-
els, nor in UProt.
To date, therapies with activated vitamin D are only approved for treating secondary hyper-
parathyroidism in CKD; a large body of experimental and clinical data, however, suggests that
vitamin D and its analogues positively affect several factors enhancing the progression of CKD,
like anemia, urinary protein excretion, activation of renin-angiotensin system and inflamma-
tion [21–25]. Despite some studies have suggested greater clinical benefits with paricalcitol
than with calcitriol, no study has directly compared the two drugs.
Hence, our work hypothesis was to evaluate in a randomized trial the effects of paricalcitol
versus calcitriol on Hb levels in patients with moderate-severe CKD. Our effort was to enroll
patients with normal concentrations of calcium, phosphate and PTH (according to their CKD
Fig 2. Effects of calcitriol (Group Calcitriol, dashed lines) and paricalcitol (Group Paricalcitol, solid lines) on hemoglobin plasma levels throughout
the study.Data are expressed as means ± SD. Abbreviations: T0, baseline levels; T2, T4 and T6, values after 2, 4 and 6 months of follow-up with both drugs.
* = p<0.05 (minimum value) vs T0; § = p<0.05 (minimum value) vs respective period of Group CALC
doi:10.1371/journal.pone.0118174.g002
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stage) and no clinical or laboratory sign of inflammation, since in most clinical studies the ben-
eficial effects of vitamin D on Hb levels were observed in patients with CKD with sustained lev-
els of inflammation and elevated PTH values, considered as important cofactors of anemia.
The present study confute this view, showing that the beneficial effect of paricalcitol on Hb
plasma levels occurred independently of any change in calcium-phosphate-PTH axis, in pres-
ence of normal concentrations of inflammatory markers and with no modification in iron bal-
ance or ESA doses. And, indeed, statistics clearly demonstrates that paricalcitol represents an
independent effector of Hb changes, excluding any role for confounding factors like ACE-I use
and diabetes, whose prevalence was greater in Calcitriol Group. Our study indirectly confirms
recent data by Patel et al. showing that the decline in Hb concentrations in CKD patients with
low levels of both 25- and 1,25-vitamin D resulted fully independent of the inflammatory status
and of PTH concentrations [8].
It is noteworthy that the amelioration of Hb concentration occurred in presence of unex-
pectedly declining values of GFR during the follow-up. Different studies, however, have sug-
gested that paricalcitol may spuriously enhance the production of creatinine, negatively
influencing the calculation of eGFR. Agarwal et al. have recently shown that creatinine produc-
tion increased after one week of oral paricalcitol, but returned to baseline levels after its discon-
tinuation [26]. Alborzi et al. have also demonstrated in patients with stage 3 CKD randomly
assigned to different doses of paricalcitol that iothalamate clearance did not vary at any dosage
after 1-month treatment [24]. Comparable findings have been described with oral calcitriol,
Fig 3. Effects of calcitriol (Group Calcitriol, dashed lines) and paricalcitol (Group Paricalcitol, solid lines) on urinary protein excretion/GFR ratio
throughout the study.Data are expressed as means ± SE. Abbreviations: T0, baseline levels; T2, T4 and T6, values after 2, 4 and 6 months of follow-up
with both drugs.
doi:10.1371/journal.pone.0118174.g003
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which depressed creatinine clearance, but did not affect inulin clearance [27, 28]. Therefore, in
both groups the observed decline in GFR could only be apparent; accordingly, the slight decline
in Hb values observed in Calcitriol patients could be a consequence of the higher prevalence of
diabetes or the greater use of ACE-I in this group, even if these factors did not affect the
statistical analysis.
The second interesting finding was the significant decrease in urinary protein excretion ob-
served in patients under paricalcitol. Despite the large variability of data and the limited power
of our study to detect a true effect on proteinuria, the changes between the two groups after ex-
posure to the drugs were statistically significant, with patients of Calcitriol Group exhibiting
steady values of proteinuria and those under paricalcitol showing a reduced protein excretion;
indeed, the UProt/GFR ratio showed a clear tendency to decline in patients of Paricalcitol
Group, but remained constant in calcitriol patients, despite the greater use of ACE-I in this
latter group.
The anti-proteinuric effect of paricalcitol has already been evidenced in both experimental
[29, 30] and clinical studies [26, 31], and is probably mediated by a direct suppression of RAS
promoter gene by paricalcitol [32], since it seems to be additive to the antiproteinuric effects of
“peripheral” RAS inhibitors [21], and is not accounted for by blood pressure reduction during
treatment. In our patients, in fact, BP remained constant throughout the follow-up period in
both arms of the study.
A role for the reduced inflammation after paricalcitol in determining our results can be rea-
sonably excluded, since our patients started from CRP values well below the highest normal
value and can conceivably be considered not inflamed. We did not measure more accurate
markers of inflammation, but several studies have clearly demonstrated that CRP levels posi-
tively correlate with the severity of anemia and EPO resistance in CKD patients, and that CRP
concentrations closely reflect Interleukin-6 levels [33–36]. Alborzi et al. found a significant de-
crease in CRP (-50%) in 16 patients receiving paricalcitol for 1 month; these patients, however,
started from CRP values 3–4 fold higher than ours and CRP levels still exceeded normal values
at end of follow-up [24]. Therefore, the anti-inflammatory effects of paricalcitol in our patients
seem negligible. It should be noted, however, that different studies have not confirmed the
anti-inflammatory effects of Vitamin D derivatives [32, 37], questioning whether vitamin D
supplementation may be considered an actual strategy to correct inflammation in CKD pa-
tients. Our results overcome these doubts, showing the independent effect of paricalcitol on
Hb levels.
The present study has some limits. First, patients of both groups were highly selected; this
selection, however, was necessary to minimize potential determinants of renal anemia, but it
seems obvious that the beneficial effects of paricalcitol are extensible to all CKD patients. Sec-
ond, we did not measure basal levels of vitamin D; Alborzi et al., however, showed that parical-
citol administration does not influence even low vitamin D concentrations, indirectly
suggesting that the results after paricalcitol are independent from vitamin D plasma levels [24].
Third, the study lacks a placebo group, which could have better clarified the exact role of calci-
triol in GFR reduction and urinary protein excretion. Last, it should be kept in mind that our
study evaluates a laboratory outcome, which represents a surrogate of a clinical outcome; to
study “hard” clinical outcomes requires longer trials and a greater number of patients.
The strength of the study, conversely, reside in the optimal clinical and metabolic control of
our CKD patients, which was carefully maintained throughout the study, the first randomized
study which compared the extra-calcium homeostasis effects of calcitriol and paricalcitol.
In conclusion, our study shows for the first time that paricalcitol, compared to calcitriol, ex-
erts a beneficial effect on Hb levels in patients with advanced CKD independent of several con-
founding factors involved in anemia pathogenesis, like inflammation and PTH levels. Our data
Paricalcitol Effect on CKD Anemia
PLOS ONE | DOI:10.1371/journal.pone.0118174 March 17, 2015 10 / 12
suggest a potential adjunctive role for this substance in the overall management of patients
with CKD, mostly considering the stability of calcium, phosphate and PTH levels during a
low-dose treatment.
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